Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

80 results
Display

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current advances in pharmacological treatments for patients with COVID-19

Kim SB, Yeom JS

Since the coronavirus disease 2019 (COVID-19) outbreak, more than 150 million people in over 200 countries have been infected, with over 3 million people dying due to it, as of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY

Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

Background/Aims: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current and future strategies for the treatment of chronic hepatitis C

Alshuwaykh O, Kwo PY

Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study

Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH

Background/Aim: This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods: A total of 242 patients with chronic hepatitis C virus (HCV) genotype...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals

Lee DH, Ryu SH, Myung Hj, Shin YJ, Lee SH, Park TY, Moon JS

The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
COVID-19 Antiviral and Treatment Candidates: Current Status

Españo E, Kim D, Kim J, Park SK, Kim JK

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 has severely impacted global health and economy. There is currently no effective approved treatment for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH

Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis

Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML

Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Drug-drug interactions with direct-acting antivirals — less is more

Wong GLH

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Zoster sine herpete: a review

Zhou J, Li J, Ma L, Cao S

Zoster sine herpete (ZSH) is one of the atypical clinical manifestations of herpes zoster (HZ), which stems from infection and reactivation of the varicella-zoster virus (VZV) in the cranial nerve,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Small Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Fusion by Targeting Cavities on Heptad Repeat Trimers

Kandeel M, Yamamoto M, Al-Taher A, Watanabe A, Oh-hashi K, Park BK, Kwon HJ, Inoue Ji, Al-Nazawi M

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a newly emerging viral disease with fatal outcomes. However, no MERS-CoV-specific treatment is commercially available. Given the absence of previous structure-based drug discovery...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B

Cho YY, Chang Y, Nam JY, Cho Hk, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ

Background/Aims: Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF). We sought to determine the long-term...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database

Park GC, Hwang S, Kim MS, Jung DH, Song GW, Lee KW, Kim JM, Lee JG, Ryu JH, Choi DL, Wang HJ, Kim BW, Kim DS, Nah YW, You YK, Kang KJ, Yu HC, Park YH, Lee KJ, Kim YK

BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vaccines and Treatment of Coronavirus Disease 2019

Choe PG

In December 2019, a new strain of betacoronavirus, severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Subsequently, the virus quickly spread worldwide...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Kwo P, Dronamraju D

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH

BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea

Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK

BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr